A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
NCT04814615
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
89Zr-daratumumab PET/CT
Sponsor
Hoag Memorial Hospital Presbyterian